

**In the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-43 (Cancelled)

44. (Currently Amended) A therapeutic pharmaceutical composition comprising

a mixture including

(a) at least one opioid analgesic selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone,  $\beta$ -hydroxy-3-methylfentanyl, levo- $\alpha$ -acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanyl, sufentanil, tilidine, tramadol and a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph of any of the foregoing;

(b) a gel-forming polymer; and polyethylene oxide;

(c) at least one disintegrant selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and

~~(e)(d)~~ a nasal tissue irritant, wherein the composition prevents the composition functions such that less than about 45% 46% of the total amount of opioid analgesic in the composition from being is recovered when the about 490 mg. of the composition is contacted with 15 ml of water.

Claims 45-49 (Cancelled)

50. (Currently Amended) A therapeutic pharmaceutical composition comprising.

a mixture including

(a) at least one opioid analgesic selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone,  $\beta$ -hydroxy-3-methylfentanyl, levo- $\alpha$ -acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone,

pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tilidine, tramadol and a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph of any of the foregoing;

- (b) a gel forming polymer polyethylene oxide at about 3 to 40% by weight; and
- (c) a surfactant at about 1 to 10% by weight;
- (d) at least one disintegrant at about 2 to 25% by weight, wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and
- (e) wherein the composition prevents the composition functions such that less than about 45% 46% of the total amount of opioid analgesic in the composition from being is recovered when the about 490 mg. of the composition is contacted with 15 ml of water.

Claims 51-59 (Cancelled)

60. (New) A therapeutic pharmaceutical composition comprising:

a mixture including

- (a) at least one opioid analgesic selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone,  $\beta$ -hydroxy-3-methylfentanyl, levo- $\alpha$ -acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tilidine, tramadol and a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph of any of the foregoing;
- (b) polyethylene oxide at about 3 to about 40 percent by weight;
- (c) at least one disintegrant at about 2 to 25 percent by weight wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and
- (d) sodium lauryl sulfate at about 1 to 10 percent by weight.

61. (New) The therapeutic pharmaceutical composition of claim 44, further comprising an emetic.
62. (New) The therapeutic pharmaceutical composition of claim 44, wherein the polyethylene oxide has an average molecular weight ranging from about 300,000 to about 5,000,000.
63. (New) The therapeutic pharmaceutical composition of claim 44, wherein the pharmaceutical composition is in unit dose form.
64. (New) The therapeutic pharmaceutical composition of claim 44, wherein the pharmaceutical composition is in a suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.
65. (New) The therapeutic pharmaceutical composition of claim 44, wherein the analgesic is present in an amount of about 0.5 to about 25 percent by weight.
66. (New) The therapeutic pharmaceutical composition of claim 44, wherein the analgesic comprises hydrocodone or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.
67. (New) The therapeutic pharmaceutical composition of claim 44, wherein the analgesic comprises oxycodone or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.
68. (New) The therapeutic pharmaceutical composition of claim 44, wherein the analgesic comprises morphine or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

69. (New) The therapeutic pharmaceutical composition of claim 44, wherein the analgesic comprises codeine or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.
70. (New) The therapeutic pharmaceutical composition of claim 44, wherein the analgesic comprises hydromorphone or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.
71. (New) The therapeutic pharmaceutical composition of claim 44, wherein the analgesic comprises propoxyphene or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.
72. (New) The therapeutic pharmaceutical composition of claim 44, wherein the analgesic comprises tramadol or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.
73. (New) The therapeutic pharmaceutical composition of claim 44, wherein the analgesic comprises meperidine or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.
74. (New) The therapeutic pharmaceutical composition of claim 44, wherein the analgesic comprises methadone or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.
75. (New) The therapeutic pharmaceutical composition of claim 44, wherein the analgesic comprises pentazocine or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

76. (New) The therapeutic pharmaceutical composition of claim 44, wherein the disintegrant comprises crospovidone.
77. (New) The therapeutic pharmaceutical composition of claim 67, wherein the disintegrant comprises crospovidone.
78. (New) The therapeutic pharmaceutical composition of claim 50, further comprising an emetic.
79. (New) The therapeutic pharmaceutical composition of claim 50, wherein the polyethylene oxide has an average molecular weight ranging from about 300,000 to about 5,000,000.
80. (New) The therapeutic pharmaceutical composition of claim 50, wherein the pharmaceutical composition is in unit dose form.
81. (New) The therapeutic pharmaceutical composition of claim 50, wherein the pharmaceutical composition is in a suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.
82. (New) The therapeutic pharmaceutical composition of claim 50, wherein the analgesic is present in an amount of about 0.5 to about 25 percent by weight.
83. (New) The therapeutic pharmaceutical composition of claim 50, wherein the analgesic comprises hydrocodone or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

84. (New) The therapeutic pharmaceutical composition of claim 50, wherein the analgesic comprises oxycodone or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

85. (New) The therapeutic pharmaceutical composition of claim 50, wherein the analgesic comprises morphine or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

86. (New) The therapeutic pharmaceutical composition of claim 50, wherein the analgesic comprises codeine or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

87. (New) The therapeutic pharmaceutical composition of claim 50, wherein the analgesic comprises hydromorphone or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

88. (New) The therapeutic pharmaceutical composition of claim 50, wherein the analgesic comprises propoxyphene or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

89. (New) The therapeutic pharmaceutical composition of claim 50, wherein the analgesic comprises tramadol or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

90. (New) The therapeutic pharmaceutical composition of claim 50, wherein the analgesic comprises meperidine or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

91. (New) The therapeutic pharmaceutical composition of claim 50, wherein the analgesic comprises methadone or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

92. (New) The therapeutic pharmaceutical composition of claim 50, wherein the analgesic comprises pentazocine or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

93. (New) The therapeutic pharmaceutical composition of claim 50, wherein the disintegrant comprises crospovidone.

94. (New) The therapeutic pharmaceutical composition of claim 84, wherein the disintegrant comprises crospovidone.

95. (New) The therapeutic pharmaceutical composition of claim 60, further comprising an emetic.

96. (New) The therapeutic pharmaceutical composition of claim 60, wherein the polyethylene oxide has an average molecular weight ranging from about 300,000 to about 5,000,000.

97. (New) The therapeutic pharmaceutical composition of claim 60, wherein the pharmaceutical composition is in unit dose form.

98. (New) The therapeutic pharmaceutical composition of claim 60, wherein the pharmaceutical composition is in a suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

99. (New) The therapeutic pharmaceutical composition of claim 60, wherein the analgesic is present in an amount of about 0.5 to about 25 percent by weight.

100. (New) The therapeutic pharmaceutical composition of claim 60, wherein the analgesic comprises hydrocodone or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

101. (New) The therapeutic pharmaceutical composition of claim 60, wherein the analgesic comprises oxycodone or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

102. (New) The therapeutic pharmaceutical composition of claim 60, wherein the analgesic comprises morphine or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

103. (New) The therapeutic pharmaceutical composition of claim 60, wherein the analgesic comprises codeine or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

104. (New) The therapeutic pharmaceutical composition of claim 60, wherein the analgesic comprises hydromorphone or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

105. (New) The therapeutic pharmaceutical composition of claim 60, wherein the analgesic comprises propoxyphene or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.



106. (New) The therapeutic pharmaceutical composition of claim 60, wherein the analgesic comprises tramadol or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

107. (New) The therapeutic pharmaceutical composition of claim 60, wherein the analgesic comprises meperidine or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

108. (New) The therapeutic pharmaceutical composition of claim 60, wherein the analgesic comprises methadone or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

109. (New) The therapeutic pharmaceutical composition of claim 60, wherein the analgesic comprises pentazocine or a pharmaceutically acceptable salt, derivative, analog, homologue, or polymorph thereof.

110. (New) The therapeutic pharmaceutical composition of claim 60, wherein the disintegrant comprises crospovidone.

111. (New) The therapeutic pharmaceutical composition of claim 101, wherein the disintegrant comprises crospovidone.